Table 7.
siRNA in clinical trials.
| Target mRNA/Delivery System | Clinical Trial/Results | Disease | Number |
|---|---|---|---|
| PKN3 */liposome | Phase 1/well tolerated | Colorectal cancer | NCT00938574 |
| RRM2 */polymer | Phase 1a/well tolerated | Unresectable solid tumors | NCT00689065 |
| HSP47 */lipid | Phase I | Liver fibrosis | NCT02227459 |
| PLK1 */lipid | Phase I | Unresectable colorectal, pancreas, gastric, breast, ovarian and esophageal cancers with hepatic metastases | NCT01437007 |
| KRASG12D */ | Phase I/IIa Phase II |
Pancreatic carcinoma |
NCT01188785 NCT01676259 |
| PKN3 */polymer | Phase Ib/IIa | metastatic pancreatic adenocarcinoma | NCT018086389 |
* PKN3: expression of protein kinase N3; HSP47: Heat shock protein 47; PLK1: polo-like kinase-1; KRASG12D: Kirsten rat sarcoma virus mutation G12D.